Media & Analysis
NewsContact person
Below you will find the latest news from MVA. You can also sign up to our newsletter MVA Update.
MVA Update is an electronic newsletter providing you with news about MVA and an overview of our events and other relevant events in Medicon Valley. You can also check out our calendar for more information about life science events in the region.
If you have any questions regarding our news section or media inquiries then please contact David Munis Zepernick, Head of Press on +45 2498 1668.
Screening for type-1 Diabetes – Presentation and discussion of the Danish-Swedish DiaUnion-project at the Political Festival “Folkemødet”
Type 1 diabetes is an incurable autoimmune disease that strikes randomly and independently of personal lifestyle. 50,000 Swedes and 34,560 Danes are affected by type 1 diabetes. The disease requires life-long, complicated treatment with insulin and places a heavy burden on the patient around the clock. Therefore, not even a third of patients reach the treatment target of 52-53 mmol/mol, resulting in debilitating complications and overmortality. The direct medical costs of type 1 diabetes...
Call for HALRIC cross-border research and innovation pilot project proposals. Deadline 8th of June!
MVA is happy to announce that the first call for HALRIC pilot projects is now open until the 8th of June 2023! The aim is to connect and increase the use of research infrastructures and expertise in the Öresund-Kattegat-Skagerrak-Hamburg (ÖKS-Hamburg) region. The project consortia welcomes applications from industry, clinics, and academia who have a research and/or innovation question within Life Science that would require the use of minimum one research infrastructure in the ÖKS-Hamburg...
MVA-members DNB and Back Bay Life Science Advisors form strategic partnership
DNB and Back Bay Life Science Advisors have announced a strategic partnership to drive global healthcare growth and innovation. DNB will make a financial investment in Back Bay to formalize the Partnership, which will provide strategic advisory and investment banking capabilities across the spectrum of development and commercialization to global biopharma, medtech, healthtech, diagnostic and healthcare service companies, ranging from pre-clinical startups to global multinationals. “DNB’s...
Alligator Bioscience Receives FDA Orphan Drug Designation for Mitazalimab in Pancreatic Cancer
MVA-member company, Lund-based Alligator Bioscience, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead asset mitazalimab for the treatment of pancreatic cancer. "This designation is a key milestone for our lead asset mitazalimab, which is producing outstanding clinical results in its Phase 2 trial in pancreatic cancer," said Søren Bregenholt, CEO of Alligator Bioscience. "Orphan designation confers significant benefits in the...
“From nanotechnology to mRNA therapies and what’s to come” Talks at the Square with Robert Langer – BII event with former MVA Annual Summit keynote speaker
On May 26th, MVA-member, BioInnovation Institute (BII), is thrilled to welcome Professor at the Massachusetts Institute of Technology (MIT) and Chair of the Scientific Advisory Board at BII, Robert Langer, as he will host ‘Talk at the Square’! Program of the day 14-14.30 Doors open 14.30-14.40 Introduction to BII and subject of the day 14.40-15.10 From nanotechnology to mRNA therapies and what’s to come 15.10-15.30 Fireside chat and questions 15.30-15.50 Informal networking and closing...
Scientists create the first CRISPR-based drug candidate targeting the microbiome
The fact that the microbiome field is a Medicon Valley stronghold has been proven once again. According to a recently published press release form The Technical University of Denmark (DTU), an international team of scientists lead by Morten Otto Alexander Sommer, professor at MVA-member DTU Biosustain (and former MVA Vice chairman of the Board and founding father of the MVA Microbiome Network) has now engineered the first published CRISPR-based candidate for a drug that targets E. coli...
MVA-member company Mercodia announces the opening of a US bioanalytical laboratory
MVA-member Mercodia, a Swedish biotech company focused on providing bioanalytical services and biomarker assays to the pharmaceutical industry and academia, announced that the company is expanding its capabilities to provide bioanalytical testing for preclinical and clinical programs with the opening of a service facility in the USA. The new US bioanalytical laboratory represents an expansion of Mercodia's capabilities and is in line with the company's business strategy to provide outsourced...
Meet both MVA’s newly elected chairman Niels Abel Bonde and veteran vice chairman Ulf G. Andersson in the newly published edition of Life Science Sweden
Following this year's Ordinary General Assembly 19th of April, Life Science Sweden reached out to learn more about the new dynamic Danish-Swedish duo's strategic priorities for Medicon Valley Alliance. Read the full interview (in Swedish) online, or have patience and wait for the printed edition.
Lund University welcomes scientists and entrepreneurs for the inaugural Lund Spring Symposium, May 24-26
The inaugural Lund Spring Symposium, May 24-26, 2023, will present state-of-the-art research centered around molecular therapeutics ranging from basic research to clinical applications. The ambition is to raise the profile of Pharmacology as a cross-functional discipline in the 21st Century and to provide a forum to facilitate collaborations across academia and industry. "This gathering will be an exclusive opportunity for scientists and entrepreneurs to broaden their horizons of cutting-edge...
Is artificial intelligence the future of healthcare in the Nordics? New article in the journal Futures by Associate senior lecturer Jason Tucker, Malmö University
The Nordic countries' national strategies point to the growing scale and scope of AI in healthcare as inevitable and essential. But the future isn’t set, and citizens must be involved in which path to take, says researcher Jason Tucker: According to Tucker, the Nordic countries' national AI strategies frame private sector implemented AI as the only solution to achieve efficiency. But if we follow this path, public healthcare will end up guided by private sector interests. We are already on our...